Gynecologic Cancer News

Cemiplimab extended OS compared with single-agent chemotherapy for women with recurrent cervical cancer, according to randomized phase 3 study results published in The New England Journal of Medicine.

Selinexor prolonged PFS compared with placebo among women with advanced or recurrent endometrial cancer, according to topline data released by the agent’s manufacturer.

American Association for Cancer Research released a first-of-its-kind report detailing the impact of the COVID-19 pandemic on the cancer community, both in patient care and research practice.

Trametinib should be a new standard of care for women with recurrent low-grade serous carcinoma, according to study published in The Lancet that showed a 52% reduction in risk for disease progression or death vs. current treatment options.

Patients with cancer had few differences in reported adverse events compared with people without cancer after receiving COVID-19 vaccines, according to study results published in JNCCN — Journal of the National Comprehensive Cancer Network.

Lenvatinib plus pembrolizumab conferred significantly longer PFS and OS than chemotherapy among women with advanced endometrial cancer, according to randomized, phase 3 trial results published in The New England Journal of Medicine.

Germline microRNA-based biomarkers accurately predicted grade 2 or higher immune-related adverse events associated with anti-PD-1/PD-L1 therapy among patients with various cancer types, according to study results.

President Joe Biden has unfinished business with cancer.

Among patients with high-risk early-stage epithelial ovarian cancer, 72% had at least one symptom, the most common of which was abdominal or pelvic pain, according to a retrospective study in Obstetrics & Gynecology.

Pembrolizumab showed strong and lasting antitumor activity in women with previously treated, advanced microsatellite instability-high or mismatch repair-deficient endometrial cancer, according to a study in Journal of Clinical Oncology.